Best guess would be Fentanyl Buccal (generic of Orexo's Abstral) which went off patent last year. Just thinking about the fact that Actavis filed an ANDA and then Orexo filed patent infringement litigation which they settled last October. I still believe Actavis and Hakim are attached somehow and Mikah is just ingenious "non-affiliated" subsidiary. It's a sublingual tablet though so not entirely sure.
Buprenorphine could be a sleeper candidate. Is there a list available of what both companies currently have. If so, could hone in a bit more.
News 
Market Data 
Discover 
AI
